I'm more than happy with the reported results, which told me plenty about Directs potential. Though we were promised periodically updated survival data which is well overdue.
If you need more results, perhaps do a shareholders enquiry...
While I agree there are scientific and ethical reasons to publish results, only trials approved by regulatory agencies are required to publish.
Failure to publish phase I data is common. I believe there are estimates that only half of the clinical trials in the US are published.
In the case of a small company like NWBO, there would (past tense) have been positive PR drivers to publish the data. If they publish now, would not the time lapse would be fodder for AF et al.?
News 
Market Data 
Discover 
